Not logged inEfficacy and Safety of Efdamrofusp Alfa versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration A Randomized, Double-Masked, Active-Controlled, Noninferiority, Phase II Trial
Sun, Junran; Song, Yanping; Gong, Yuanyuan; Tao, Liming; Wang, Hong; Shu, Xiangwen; Wen, Ying; Cui, Ling; Ye, Jian; Lu, Shujie; Deng, Junjie; Li, Haoyu; Xu, Yihua; Qian, Lei; Wu, Zhifeng; Bi, Yanlong; Liu, Qinghuai; Xu, Xiangzhong; Wu, Miaoqin; Zhang, Jinglin; Hao, Jilong; Tong, Jianping; Dai, Hong; Wang, Feng; Zhao, Mingwei; Mao, Junfeng; Li, Chaopeng; He, Tao; Pei, Cheng; Liu, Xiaoling; Wang, Xian; Li, Mingxin; Wang, Wei; Zheng, Qinxiang; Guan, Huaijin; Peng, Hui; Fan, Ke; Zhang, Wenfang; Zhu, Dan; Yu, Songping; Wei, Wenbin; Ding, Lin; Li, Jinying; Lu, Peirong; Yan, Ming; Liu, Wei; Jia, Huixun; Sun, Xiaodong .png)
Share.png)
SaveIBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I studyLemech, C.; Sun, Y.; Nagrial, A.; Wu, X.; Morris, M.; Ning, F.; Yang, J.; Pan, Y.; Cai, J.; Lu, P.; Zhang, T.; Qiu, F.; Hu, C.; Zhang, M.; Liu, Z.; Han, G.; Nie, J.; Teng, C.; Zhou, H.; Day, D. Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
